SAN DIEGO, April 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit.  Captioned Quinn v. Viatris Inc., No. 25-cv-00466 (W.D. Pa.), the Viatris class action lawsuit charges Viatris and certain of Viatris' top executives with violations of ...

Core Viewpoint - A class action lawsuit has been filed against Viatris Inc. for allegedly providing misleading information regarding the FDA's warning letter related to its Indore, India facility, which impacted the company's operations [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - Investors have until June 3, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - The complaint claims that Viatris misrepresented the significance of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2].

NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=141957&from=4CLASS PERIOD: August 8, 2024 to Februar ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Viatris between August 8, 2024 and February 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 09, 2025 (GLO ...

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. due to alleged misrepresentation of the impact of a warning letter from the FDA regarding its Indore, India facility, which led to a significant decline in stock price following disappointing financial results [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Viatris securities between August 8, 2024, and February 26, 2025 [1]. - The complaint claims that the defendants misrepresented the severity of the FDA's warning letter, downplaying it as a "minor headwind" for the company [2]. - Following the announcement of disappointing fiscal 2025 guidance attributed to the warning letter and import alert, Viatris' stock price fell from $11.24 to $9.53, a decline of approximately 15.21% in one day [2]. Group 2: Investor Information - Investors who acquired shares of Viatris are encouraged to contact the law firm before the lead plaintiff motion deadline on June 3, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation [3].

Market Overview - The Age-related Macular Degeneration (AMD) Market grew from USD 10.45 billion in 2023 to USD 11.10 billion in 2024, with a projected CAGR of 6.67%, reaching USD 16.43 billion by 2030 [2][15]. - Recent advancements in diagnostic imaging and molecular biology are facilitating early detection and intervention strategies for AMD, significantly altering treatment trajectories for both dry and wet forms of the disease [3]. Treatment Innovations - The market is witnessing a shift from traditional reactive approaches to proactive, data-driven methodologies, emphasizing precision medicine tailored to individual patient profiles [4]. - Companies are recalibrating their portfolios to incorporate emerging therapies and integrated treatment modalities, enhancing patient outcomes and maximizing market share [5]. Regional Trends - North America benefits from robust healthcare infrastructure and high prevalence of chronic conditions, leading to streamlined early diagnosis and intervention for AMD [6]. - In Europe, regulatory reforms and increased awareness are driving market expansion, with emerging economies recognizing the importance of modern ophthalmological care [7]. - The Asia-Pacific region is experiencing rapid growth due to economic development and improved healthcare delivery systems, creating significant demand for both conventional and advanced treatment options [8]. Competitive Landscape - Numerous established and emerging companies are actively shaping the AMD management landscape, with significant developments from firms like AbbVie Inc., Novartis AG, and Bayer AG [9][14]. - Strategic recommendations for industry leaders include prioritizing clinical research, investing in diagnostic modalities, and fostering collaborations with academic institutions to validate emerging therapies [10][11]. Strategic Recommendations - Companies should align operational strategies with evolving regulatory frameworks and emphasize agile supply chain management to balance risk while capitalizing on market opportunities [11][12]. - Diversifying portfolios across pharmaceutical and surgical interventions can mitigate risks associated with market saturation and competitive overlap [12][13].

Core Insights - Opus Genetics is focused on developing innovative gene therapy treatments for inherited retinal diseases (IRDs) and has made significant progress in its transformation and pipeline [1][2] - The company raised $21.5 million through a public offering and private placement, enhancing its cash position to approximately $50.7 million, which supports key milestones for its gene therapy candidates [2][9] - The acquisition of Opus Genetics has strengthened the company's pipeline, which now includes seven adeno-associated virus (AAV)-based gene therapy assets targeting specific IRDs [4][17] Financial Performance - For the year ended December 31, 2024, Opus reported a net loss of $57.5 million, or $2.15 per share, compared to a net loss of $10.0 million, or $0.46 per share, in 2023 [15][25] - License and collaborations revenue decreased to $11.0 million in 2024 from $19.0 million in 2023, primarily due to the absence of a milestone payment received in 2023 [12][25] - General and administrative expenses increased to $18.2 million in 2024 from $12.0 million in 2023, attributed to transaction costs related to the acquisition and other operational expenses [13][25] Pipeline and Clinical Trials - The lead gene therapy candidate, OPGx-LCA5, is in a Phase 1/2 trial and has shown positive results, with visual improvement observed in all adult patients after one year [9][18] - OPGx-BEST1 is expected to enter clinical trials in 2025, targeting IRDs associated with mutations in the BEST1 gene [9][18] - The LYNX-2 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% has completed enrollment, with topline data expected in mid-2025 [9][18] Strategic Direction - The company aims to achieve several key milestones in 2025, including up to four clinical trial data readouts and the initiation of new trials for its gene therapy candidates [2][10] - A Type D meeting with the FDA was held to discuss the regulatory path for OPGx-LCA5, indicating proactive engagement with regulatory authorities [9][18] - The company is also seeking a strategic partner to advance the late-stage development of APX3330, a novel oral REF-1 inhibitor for diabetic retinopathy [9][18]